NHT

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
화요일, 4월 30, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Education, PFS, Abbreviated New Drug Application, European Patent Office, Experiment, Breast, NET, ASCO, RCC, Associate, Translation, European Medicines Agency, Hearing, PIN, Drug development, European Patent Convention, Metastasis, Conference, Liver disease, ADC, Stada Arzneimittel, Tablet, Baylor College of Medicine, Distinguishing, Therapy, NHT, Calendar, BIRC, Huntsman Cancer Institute, OS, Dean (education), Docetaxel, PKMYT1, Checkmate, Prostate cancer, ITT, EPO, USP1, University, PARP, Immunotherapy, Superior, PLK4, Patent, Royalty payment, Patient, Society, Acquisition, Translational research, Neoplasm, Share repurchase, Annual general meeting, Baylor University

Exelixis’ 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.

Key Points: 
  • Exelixis’ 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter ended March 31, 2024, Exelixis earned $39.6 million in royalty revenues.
  • In January, Exelixis announced the appointments of Mary C. Beckerle, Ph.D., and S. Gail Eckhardt, M.D., to the Exelixis Board of Directors, effective January 5, 2024.
  • Exelixis management will discuss the company’s financial results for the first quarter of 2024 and provide a general business update during a conference call beginning at 5:00 p.m.

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
화요일, 2월 6, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Molecule, Royalty payment, Conference, Liver disease, Calendar, Breast, Immunotherapy, RCC, PIN, ASCO, NHT, Progression-free survival, Safety, FDA, PLK4, ADC, ITT, PKMYT1, Associate, University, Baylor University, PARP, USP1, Society, Neck, Science, Acquisition, Biology, Superior, Huntsman Cancer Institute, Dean (education), Metastasis, PFS, Translational research, Drug development, Distinguishing, Head, Food, NET, Baylor College of Medicine, Cancer, Share repurchase, BIRC, OS, SCCHN, Neoplasm, Congress, National Cancer Institute, Abbreviated New Drug Application, Research, Docetaxel, Translation, Prostate cancer, Therapy, ESMO, Education, Experiment, Checkmate, Pharmaceutical industry

In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.

Key Points: 
  • In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter and year ended December 31, 2023, Exelixis earned $40.7 million and $148.5 million, respectively, in royalty revenues.
  • In October 2023, detailed results were presented from the phase 3 CABINET pivotal trial at the 2023 ESMO Congress.
  • Exelixis management will discuss the company’s financial results for the fourth quarter and fiscal year of 2023 and provide a general business update during a conference call beginning at 5:00 p.m.

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Retrieved on: 
목요일, 1월 25, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Exelixis, Huntsman Cancer Institute, Patient, Prostate cancer, PST, Progression-free survival, NHT, OS, ASCO, Survival, Clinical research, University, Society, Metastasis, RECIST, PFS, BIRC, ITT

The detailed findings are being presented during Oral Abstract Session A: Prostate Cancer at 7:55 a.m. PST on January 25 at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU).

Key Points: 
  • The detailed findings are being presented during Oral Abstract Session A: Prostate Cancer at 7:55 a.m. PST on January 25 at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU).
  • The PFS analysis was conducted in the first 400 randomized patients in the intent-to-treat (PFS ITT) population and per protocol.
  • While a trend toward OS improvement was observed, the data were immature and did not meet the threshold for statistical significance.
  • The PFS benefit and the trend for an OS benefit were observed across subgroups of high-risk populations, as presented in Table 1.

NH TherAguix appoints Jean-Philippe DEL as Chief Financial Officier

Retrieved on: 
월요일, 1월 15, 2024
NHT, CFO, Radiation, University, Neoplasm, Del, Mazars, Euronext Paris, Jean-Philippe, Pharmaceutical industry

NH TherAguix appoints Jean-Philippe Del as Chief Financial Officer.

Key Points: 
  • NH TherAguix appoints Jean-Philippe Del as Chief Financial Officer.
  • Paris, January 15th, 2024 – NH TherAguix SA (“NHT”), a Phase II clinical stage biotech company developing AGuIX®, a nanodrug to treat radiotherapy eligible tumours and metastases across oncology indications, today announced the appointment of Jean-Philippe Del as Chief Financial Officer (CFO).
  • Jean-Philippe Del brings more than 18-year experience in the biotechnology industry from Transgene (Euronext Paris) where he last was CFO.
  • Vincent Carrère, Chief Executive Officer of NH TherAguix stated “We are delighted to bring Jean-Philippe onboard.

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

Retrieved on: 
일요일, 1월 7, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Associate, Baylor College of Medicine, PKMYT1, BRCA, FDA, Breast, Progression-free survival, Society, Insilico Medicine, Cancer, Distinguishing, Translational research, Neck, PLK4, Workforce, Conference, Translation, Biology, IND, Colorectal cancer, MSN, NHT, University, PARP, Doctor of Philosophy, Calendar, District court, Harvard University, Immunotherapy, Food, Johnson & Johnson, NET, Huntsman Corporation, Cell adhesion, Therapy, TKI, USP1, Neoplasm, Experiment, Patient, NCI, Corporation, Baylor University, Huntsman Cancer Institute, Research, Acquisition, Dean (education), Education, Pnet, Head, Shareholder, Share repurchase, PFS, ADC, Pharmaceutical industry

The preliminary 2023 financial information presented in this press release has not been audited and is subject to change.

Key Points: 
  • The preliminary 2023 financial information presented in this press release has not been audited and is subject to change.
  • The complete Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results are planned for release after market on Tuesday, February 6, 2024.
  • Exelixis expects to substantially complete the restructuring in the first quarter of 2024 and recognize a restructuring charge of approximately $25 million.
  • In 2024, the company expects to designate two new programs to DC status, including a small molecule PLK4 inhibitor and an additional ADC.

Nob Hill Therapeutics Awarded HHS Phase II Grant for Lung Cancer Therapy

Retrieved on: 
화요일, 10월 3, 2023
NHT, Lung, Cancer, Lung cancer, Physician, Patient, HHS, Doctor of Philosophy, Pharmaceutical industry, Medical imaging

ALBUQUERQUE, N.M., Oct. 3, 2023 /PRNewswire-PRWeb/ -- Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $2M) to develop an inhaled therapy to treat lung cancer. The funds will be used to scale-up and optimize the drug powder formulation, to test the formulation with NHT's first-of-its-kind dry powder nebulizer delivery platform technology, and to conduct other pre-IND studies.

Key Points: 
  • Nob Hill Therapeutics, a respiratory-focused healthcare company, will use the grant funds to develop an inhaled therapy to treat lung cancer.
  • ALBUQUERQUE, N.M., Oct. 3, 2023 /PRNewswire-PRWeb/ -- Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $2M) to develop an inhaled therapy to treat lung cancer.
  • Noel Greenberger, CEO of NHT, said "This grant certainly presents an exciting opportunity for Nob Hill and Lovelace Biomedical.
  • There are over 2 million lung cancer cases each year globally, and lung cancer is the leading cause of cancer-related deaths in the US and Europe.

Romantic Works of Tchaikovsky, Schumann and Casals Sing in the Hands of Cellist Bion Tsang in CANTABILE, a New Album for Cello and Orchestra Now Available Worldwide from Universal Music Group

Retrieved on: 
금요일, 4월 14, 2023
Apple Music, Royal Scottish National Orchestra, Pablo Casals, Bird, Singing, OP, NHT, Variations on a Rococo Theme, THIS, Song of the Birds, Human, Spotify, Rococo, Pyotr Ilyich Tchaikovsky, Universal Music Group, Cello Concerto (Schumann), Creativity, Science, Cello Concerto, Madness, Google Play Music, NOW, Death, Mental health, PBS, RSNO, Music

AUSTIN, Texas, April 14, 2023 /PRNewswire/ -- In his newest release, cellist Bion Tsang returns to Glasgow, Scotland for his second recording with the Royal Scottish National Orchestra and conductor Scott Yoo.  CANTABILE, available from Universal Music Group on digital platforms tomorrow, April 14, and on CD in May 2023, features two works by Tchaikovsky, Variations on a Rococo Theme (Op. 33) and Andante Cantabile (Op. 11), and Schumann's Cello Concerto, bookended by two renditions of Pablo Casals' "Song of the Birds."

Key Points: 
  • CANTABILE, available from Universal Music Group on digital platforms tomorrow, April 14, and on CD in May 2023, features two works by Tchaikovsky, Variations on a Rococo Theme (Op.
  • 11), and Schumann's Cello Concerto, bookended by two renditions of Pablo Casals' "Song of the Birds."
  • CANTABILE opens with Casals' "Song of the Birds" for cello and orchestra, setting an intention for the album's romantic arc.
  • Produced by Michael Fine, CANTABILE is distributed by Universal Music Group and available everywhere digital music is distributed including Apple Music, Spotify and Google Music.

The NHP Foundation (NHPF) Closes on $9.5M in Financing for Acquisition of 36 Naturally Occurring Affordable Units Adjacent to the Takoma Metro in Washington, D.C.

Retrieved on: 
수요일, 11월 2, 2022
NHT, Acquisition, NOAH, Partnership, Operation Pathway, Community development, Organization, Risk, SVP, Unbought Tenants' Association, Poverty, AMI, Hardship, Housing, Public sector, Tenant, Review, Garden, Leasehold estate, Association, LIHTC, Property management, District

NEW YORK, Nov. 2, 2022 /PRNewswire-PRWeb/ -- NHPF, a national not-for-profit provider of quality affordable housing, announced today that it has closed on the acquisition of Elm Gardens Apartments, a 3-story building with 36 apartments and parking spaces in the Takoma neighborhood of Washington, D.C. The acquisition is made possible via a $7.5M loan from the Low Income Investment Fund (LIIF) funded through the DC Preservation Fund, a joint venture between LIIF and the DC Department of Housing and Community Development (DHCD), and a $2M acquisition/predevelopment loan from the National Housing Trust (NHT).

Key Points: 
  • Elm Gardens marks NHPF's eighth TOPA deal in the District.
  • New construction is scheduled to commence in 2024, dependent upon a LIHTC award and soft financing from DHCD through the Housing Production Trust Fund (HPTF).
  • NHPF's Construction Management Group provides in-house resources dedicated to infrastructure review, infrastructure development and cost management.
  • Through Family-Centered Coaching, NHPF's subsidiary Operation Pathways engages with, and assists, families experiencing poverty and other hardship, to problem-solve together.

JPMorgan Chase Committing $15 Million to Increase the Supply of Climate Resilient Affordable Housing for Black, Hispanic and Latino Households

Retrieved on: 
수요일, 10월 12, 2022
Other Philanthropy, Sustainability, Consumer, Personal Finance, Residential Building & Real Estate, Climate Change, Construction & Property, Environment, Natural Disasters, Finance, Urban Planning, Utilities, Green Technology, Banking, Alternative Energy, Energy, Professional Services, Philanthropy, Other Consumer, Environmental Policy, Environmental Issues, J. P. Morgan, Color, Government, Home, Urban Institute, Electricity, Housing, Natural gas, Future, The Urban Institute, Policy, Organization, Dow Jones Industrial Average, NYSE, NPHS, LEED for Neighborhood Development, Carbon, Program, Workforce, SELF, JPMorgan Chase, Chase, New York City Council Black, Latino and Asian (BLA) Caucus, Company, Technology, Industry, Health, Â, Ecosystem, Secondary suite, Rehabilitation, Climate, Climate change, Urban, NHT, JPM, Weather, Solution, Renewable energy, Financial services, Rio Grande Valley

JPMorgan Chase announced five organizations will receive philanthropic commitments of $3 million each to scale innovative climate resilient affordable housing models.

Key Points: 
  • JPMorgan Chase announced five organizations will receive philanthropic commitments of $3 million each to scale innovative climate resilient affordable housing models.
  • This work is part of the firms $400 million five-year commitment to improve housing affordability and stability for households of color, particularly in Black, Hispanic and Latino communities.
  • More households deserve accessible options to homeownership and now more than ever we need equitable, sustainable solutions that better equip communities with affordable, climate resilient housing.
  • To address the shortage of energy-efficient and climate-resilient affordable housing, the following organizations will each receive $3 million in philanthropic capital to influence housing construction practices:
    come dream.

Nob Hill Therapeutics Awarded HHS Phase II Grant and Announces New CEO

Retrieved on: 
화요일, 8월 23, 2022
COVID-19, University, CEO, Technology, Research, VIC, Therapy, Degenerative disease, Doctor of Philosophy, Toxicity, Death, Urinary tract infection, Interim, Inhalation, Lung, SBIR, LLC, Efficiency, Knowledge, Marketing, Acquisition, HHS, NHT, Patient, Pharmaceutical industry, Management

ALBUQUERQUE, N.M., Aug. 23, 2022 /PRNewswire-PRWeb/ -- Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $1.73M) to develop an inhaled therapy to treat lung fungal infection using an innovative first-of-its-kind dry powder nebulizer delivery platform technology. The funds will be used to develop the drug powder formulation and the delivery device (DryNeb) as well as other pre-IND studies.

Key Points: 
  • ALBUQUERQUE, N.M., Aug. 23, 2022 /PRNewswire-PRWeb/ -- Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $1.73M) to develop an inhaled therapy to treat lung fungal infection using an innovative first-of-its-kind dry powder nebulizer delivery platform technology.
  • Paul J Atkins, PhD, Executive Chairman NHT, said "This is an exciting time for Nob Hill.
  • The SBIR grant award further validates the potential benefit of this delivery technology to develop therapies to treat severe lung infections."
  • "This grant is built on our successful phase I grant work conducted a year ago, which delivered encouraging animal efficacy study results.